Jonathan Baell

Jonathan Baell

Company: Lyterian Therapeutics

Job title: Executive Director, Discovery Chemistry


Harnessing the Potential of Molecular Glues to Target & Degrade Proteins Across CNS Indications 1:01 pm

CNS disease targets possess the hallmarks of molecular glue’s ability to address hard-to-drug targets, furthered still with molecular glue’s smaller size being advantageous to penetrating the BBB. Join this workshop to debate the ability, current status, and major challenges to overcome to demonstrate the untapped potential of molecular glue applications to the CNS. Highlights include:…Read more

day: Pre-Conference Day

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.